High‐density lipoprotein from end‐stage renal disease patients exhibits superior cardioprotection and increase in sphingosine‐1‐phosphate

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2362|48|2|eci.12866-eci.12866

ISSN： 0014-2972

Source： EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (ELECTRONIC), Vol.48, Iss.2, 2018-02, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Endurance training selectively increases high‐density lipoprotein‐bound sphingosine‐1‐phosphate in the plasma

By  

SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS, Vol. 28, Iss. 1, 2018-01 ,pp. : 57-64

John Wiley & Sons Inc

Access to resources Recommend Favorite

Deferasirox in thalassemia patients with end‐stage renal disease

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 91, Iss. 10, 2016-10 ,pp. : E456-E457

John Wiley & Sons Inc

Access to resources Recommend Favorite

Discrepancy of interleukin-6 levels between end-stage renal disease patients and patients with acute-phase response with increased lipoprotein(a) concentrations

By Yun K. A.   Lee W.   Min W. K.   Chun S.   Lee Y. W.   Kim S. B.   Park J. S.   Yang W. S.   Park H.   Hwang S. H.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 64, Iss. 3, 2004-06 ,pp. : 223-228

Informa Healthcare

Access to resources Recommend Favorite

Should high-flux hemodialysis be replaced by online hemodiafiltration for treating end-stage renal disease patients?

By Maduell Francisco   Moreso Francesc  

Journal of Comparative Effectiveness Research, Vol. 2, Iss. 4, 2013-07 ,pp. : 347-349

Future Medicine

Access to resources Recommend Favorite

Co‐inhibitory profile and cytotoxicity of CD57+PD‐1– T cells in end‐stage renal disease patients

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 191, Iss. 3, 2018-03 ,pp. : 363-372

John Wiley & Sons Inc

Access to resources Recommend Favorite